<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"Cervical approach":1,
"Ectopic goiter":1,
"Ectopic thyroid":1,
"Intrathoracic goiter":1,
"Substernal goiter":1,
"Thyroidectomy":6,
"Fine needle cytology":1,
"Follicular neoplasm":2,
"Hemithyroidectomy":1,
"Thyroid cancer":25,
"Total thyroidectomy":3,
"Calcitonin":1,
"Cancer registry":1,
"Database":1,
"Medullary thyroid cancer":1,
"RET proto-oncogene":1,
"Survival":2,
"Biological markers":1,
"prognosis":4,
"thyroglobulin":1,
"thyroid neoplasms":3,
"thyrotropin":1,
"Cancer stage":1,
"Iodine":2,
"Radioisotope scintigraphy":1,
"Therapeutic":1,
"Thyroid tumor":1,
"atypia of undetermined significance":2,
"fine needle aspiration":3,
"follicular lesion of undetermined significance":2,
"risk of malignancy":1,
"sub-category":1,
"thyroid cytopathology":1,
"phosphorylation of thyroid hormone receptor β1":1,
"thyroid hormone receptor β mutant":1,
"tumor suppressor":2,
"xenograft models":1,
"BRAF mutation":3,
"liquid based cytology":1,
"paediatric thyroid carcinoma":1,
"paediatric thyroid lesions":1,
"plump cells":1,
"Core needle biopsy":1,
"Malignancy":1,
"Neoplasm":1,
"Thyroid":13,
"Larynx chondrosarcoma":1,
"cartilaginous tumor":1,
"chondrosarcomas":1,
"laryngeal cancer":1,
"laryngeal chondrosarcoma":1,
"laryngeal malignancy":1,
"laryngeal tumor":1,
"larynx cancer":1,
"larynx malignancy":1,
"systematic review":1,
"Bilateral axillary approach":1,
"Robotic thyroid surgery":1,
"Robotic thyroidectomy":1,
"MOLECULAR PATHOLOGY":1,
"OK-432":1,
"Sapylin":1,
"breast cancer":5,
"modified radical mastectomy":1,
"postoperative complication":1,
"seroma formation":1,
"EZH2":2,
"RASSF2A":1,
"methylation":1,
"genitourinary":1,
"renal cell carcinoma":1,
"thyroid-like follicular carcinoma":1,
"Bethesda criteria":1,
"Bethesda recommendations":1,
"Fine-needle aspiration":3,
"Repeat FNA":1,
"Thyroid nodule":6,
"Biliary tract cancer":1,
"Ductal margin":1,
"Frozen section":1,
"Metastasis":5,
"TERT mutation":1,
"differentiated thyroid carcinoma":1,
"radioactive iodine therapy":2,
"therapy response":1,
"Differentiated thyroid cancer":3,
"Distant metastases":2,
"Radioiodine therapy":1,
"Risk stratification":2,
"atherosclerosis":2,
"childhood cancer survivors":1,
"intima-media thickness":1,
"late effects":1,
"radiotherapy":2,
"2009 revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer":1,
"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer":1,
"Decision-making":1,
"Differentiated thyroid cancer management guidelines":1,
"Recommendations":1,
"Thyroid remnant ablation":1,
"cancer radiopeptide targeting":1,
"renal cell cancer":1,
"somatostatin sst2 receptors":1,
"sst2 antagonist":1,
"WT1 protein":1,
"calretinin":1,
"carcinoembryonic antigen":1,
"claudin-4":1,
"immunohistochemistry":4,
"mesothelioma":1,
"p40":1,
"squamous cell carcinoma":2,
"Thermal ablation":2,
"papillary thyroid carcinoma":12,
"radiofrequency/microwave":1,
"ultrasound":4,
"Apoptosis":2,
"Hydroxytyrosol":1,
"Nutrition":1,
"Olive oil":1,
"Adult":1,
"Auricular thrombosis":1,
"Rhabdomyosarcoma":1,
"Venous thrombosis":1,
"18F-FDG PET/CT":1,
"Esophageal cancer":1,
"MTV":1,
"TLG":1,
"Texture analysis":1,
"the Bethesda system for reporting thyroid cytopathology":1,
"Concomitant disease":1,
"Parathyroid gland":2,
"Parathyroidectomy":2,
"Thyroid gland":3,
"Anaplastic thyroid cancer":3,
"Follicular thyroid cancer":1,
"Iodine deficiency":1,
"Iodised salt":1,
"Papillary thyroid cancer":5,
"Seafood nutrition":1,
"Thyroid nodular pathology":1,
"Urinary iodine concentration":1,
"Autoimmune thyroiditis":1,
"Breast surgery":1,
"Breast treatment":1,
"Thyroid disease":1,
"Acromegaly":1,
"Colon":1,
"carbon nanoparticles":1,
"neck lymphadenectomy":1,
"thyroid carcinoma":8,
"Glande thyroïdienne":1,
"Incidence":1,
"Néoplasmes thyroïdiens":1,
"Overdiagnosis":2,
"Surdiagnostic":1,
"airway epithelium":1,
"lung cancer":2,
"respiratory function tests":1,
"thoracic surgery":1,
"Long bones":1,
"Metastatic bone disease":1,
"Surgical treatment":1,
"BAVANS":1,
"bidirectional approach":1,
"endoscopic thyroidectomy":1,
"Cancer thyroïde":1,
"Carcinome mucineux":1,
"Mucin":2,
"Mucine":1,
"Mucinous carcinoma":1,
"TTF1":1,
"Cancer":8,
"Follicular":1,
"Radioiodine":1,
"Adverse event":1,
"Overall survival":2,
"Recurrence free survival":1,
"Thyroid lobectomy":1,
"ER-α":1,
"PKM2":1,
"PTEN":1,
"glyoxalases":1,
"prostate cancer":1,
"lymph node metastasis":1,
"microvessel density":1,
"vascular endothelial growth factor":1,
"vascular index":1,
"core-needle biopsy":1,
"Ganglioneuroma":1,
"multiple endocrine neoplasia type 2B":1,
"paraganglioma":1,
"guidelines":1,
"radioactive iodine-refractory thyroid cancer":1,
"thyroid nodules":1,
"thyroid surgery":1,
"bilaterality":1,
"multifocality":2,
"practice guidelines":1,
"predictive accuracy":1,
"recurrence":1,
"estimation models":1,
"radiation carcinogenesis":1,
"second primary cancer":1,
"lateral lymph node metastasis":1,
"level V dissection":1,
"level V metastasis":1,
"modified radical neck dissection":1,
"clear cell renal cell carcinoma metastases":1,
"contralateral adrenal gland":1,
"cytology diagnosis":1,
"pancreas":1,
"chemotherapy":1,
"intensity modulated radiotherapy":1,
"locoregional control":1,
"unresectable poorly differentiated thyroid carcinoma":1,
"BRAF":5,
"RAS":1,
"RET/PTC":2,
"papillary":2,
"cell cycle":1,
"gene expression":1,
"mitotic phase":1,
"translational research":1,
"HNC":1,
"clinical application":1,
"function":1,
"lncRNAs":1,
"mechanism":1,
"epidemiology":2,
"genetics":2,
"medullary thyroid carcinoma":3,
"medullary thyroid carcinoma—genetics":1,
"molecular biology":2,
"magnetic probe–guided excision":1,
"metastatic lymph nodes":1,
"reoperation":1,
"Mps1":1,
"TTK":1,
"aneuploidy":1,
"biomarker":2,
"target":1,
"FOXE1 polymorphism":1,
"case-control association study":1,
"functional analysis of transactivation potential":1,
"genotype":1,
"children":1,
"mutations":1,
"pediatric thyroid cancer":1,
"clinical research":1,
"quality of life":2,
"surgery":1,
"Collective cell migration":1,
"Gap junction":1,
"Rac":1,
"Single cell migration":1,
"All-trans retinoic acid (ATRA)":1,
"Drug delivery systems":1,
"Human thyroid carcinoma":1,
"Liposomes":1,
"Aging":1,
"Molecular diagnosis":1,
"AKT pathway":1,
"ERα":1,
"MCAM/CD146":1,
"Tamoxifen resistance":1,
"AGK-BRAF":1,
"ETV6-NTRK3":1,
"pediatric thyroid carcinomas":1,
"Hypothyroidism":1,
"metabolic syndrome":1,
"thyroid hormone withdrawal":1,
"Interleukin 10":1,
"Prognostic marker":1,
"Thyroid neoplasm":1,
"Tumor immunology":1,
"shoulder complaints":1,
"SEER":1,
"germ cell tumors":1,
"ovarian cancers":1,
"second cancers":1,
"cervicotomy":1,
"pain":1,
"robot":1,
"transaxillary":1,
"Enophthalmos":1,
"Idiopathic orbital inflammatory syndrome":1,
"IgG4-related disease":1,
"Orbit":1,
"Orbital fracture":1,
"Thyroid eye disease":1,
"Traumatic optic neuropathy":1,
"Drug response":1,
"esophageal squamous cell carcinoma":2,
"fibrinogen":1,
"neutrophils":1,
"Benign thyroid nodule":1,
"Microwave ablation":1,
"Radiofrequency ablation":1,
"diagnosis":1,
"head and neck ultrasound":1,
"shear wave elastography":1,
"sonography":1,
"Neuroglioma":1,
"PTPN4 PDZ domain":1,
"Peptide ligand":1,
"Salt bridge":1,
"ATA risk stratification":1,
"capsular invasion":1,
"cervical lymph node metastasis":1,
"disease-free survival":1,
"fine needle aspiration cytology":1,
"IL-27":1,
"risk":1,
"rs153109":1,
"rs17855750":1,
"single nucleotide polymorphism":2,
"fine-needle aspiration (FNA)":1,
"health care costs":1,
"thyroid cancer incidence":1,
"Adhesion":1,
"Migration":2,
"Proliferation":4,
"Renal cancer":1,
"Type 1 iodothyronine deiodinase":1,
"Cadmium":1,
"GPER":1,
"Invasion":2,
"carcinoma":2,
"Cancer thyroïdien":1,
"FDG-PET":1,
"FDOPA":1,
"Iode-124":1,
"Iodine-124":1,
"TEP-FDG":1,
"cell signaling":1,
"indoleamine-pyrrole 2,3-dioxygenase (IDO1)":1,
"interferon regulatory factor (IRF)":1,
"signal transducers and activators of transcription 1 (STAT1)":1,
"ancillary test":1,
"fine-needle aspiration biopsy":1,
"multi-institutional":1,
"salivary gland":1,
"Aged":1,
"SEER Program":1,
"fine needle aspiration cytology (FNA)":1,
"indeterminate":1,
"ultrasonography":1,
"Depression":1,
"PHQ-9":1,
"Psychosocial oncology":1,
"ATC":1,
"brigatinib":1,
"ceritinib":1,
"crizotinib":1,
"neuroblastom":1,
"14q32 region":1,
"microRNA":1,
"microTranscriptome":1,
"NEAT1":1,
"lncRNA":1,
"miR-101":1,
"YAP1":1,
"signaling pathway":1,
"GRP 78":1,
"Heat shock protein 70":1,
"Heat shock protein 90":1,
"Adenocarcinoma":4,
"Subtype":1,
"Thymus":1,
"ROCK":1,
"SP600125":1,
"multi-tyrosine kinase inhibitors":1,
"multicellular spheroids":1,
"Hyperthyroidism":2,
"Nodule":1,
"Breast cancer cell migration":1,
"Focal adhesion complex":1,
"Src/FAK/PI3K":1,
"Triiodothyronine":1,
"solid-organ transplant":1,
"standardized incidence ratio":1,
"TERT":2,
"telomerase":1,
"hobnail":1,
"next-generation sequencing":1,
"CAM assay":1,
"TT cells":1,
"neuroendocrine tumor":1,
"shikonin":1,
"elastic modulus":1,
"elastography":1,
"shear wave speed imaging":1,
"Bone tumour":1,
"Massive prosthesis":1,
"Multidisciplinary management":1,
"Pathological fracture":1,
"PD1":1,
"PDL1":1,
"anaplastic carcinoma":1,
"miR-146a":1,
"potassium iodate":1,
"Aggressive behavior":1,
"Papillary thyroid microcarcinoma":1,
"Primary tumor diameter":1,
"Total tumor diameter":1,
"Tumor diameter ratio":1,
"Hashimoto-thyreoiditis":1,
"Hashimoto’s thyroiditis":1,
"papillaris pajzsmirigy-carcinoma":1,
"cervical lymph nodes":1,
"metastases":1,
"pathology-thyroid":1,
"radiology":1,
"APC mutation":1,
"Cancer stem cells":1,
"Colorectal cancer":2,
"Dclk1":1,
"Intestinal epithelial cells":1,
"Nanoparticles":1,
"Pro-survival signaling":1,
"Self-renewal":1,
"Nodules":1,
"Thyroid hormones":2,
"Biopsy":1,
"Fine-needle":1,
"Health Services Accessibility":1,
"Han Chinese":1,
"SNPs":1,
"VEGFA":1,
"nodular goiter":1,
"FDG-PET/CT":1,
"neoadjuvant chemoradiotherapy":1,
"EMT":1,
"Glioma":1,
"LncRNA PTCSC3":1,
"Wnt signal":1,
"NIS mutations":1,
"gene transfer studies":1,
"imaging and radioiodide therapy":1,
"sodium/iodide symporter":1,
"structure/function":1,
"IGF1R":1,
"IGF2BP3":1,
"chromosomal rearrangements":1,
"Microcarcinoma":1,
"Papillary Carcinoma":1,
"Drug holiday":1,
"EGFR TKI retreatment":1,
"EGFR mutation":1,
"Exon 21 mutation":1,
"Females":1,
"Progression free survival":1,
"Anaplastic thyroid carcinoma":1,
"cucurbitacin B":1,
"doxorubicin":1,
"synergism":1,
"Thyroid transcription factor 1":1,
"expression":1,
"non-small cell lung cancer":1,
"Free anteromedial thigh perforator flap":1,
"Relaying anterolateral thigh perforator flap":1,
"Skin transplantation":1,
"Surgical flaps":1,
"Wounds and injuries":1,
"Abnormal thyroid gland":1,
"Piriform fossa":1,
"Thyroid adenoma":1,
"Birt–Hogg–Dubé syndrome":1,
"Lung bubblae":1,
"Mutation":2,
"Pneumothorax":1,
"Treatment":1,
"Immunotherapy":1,
"Myxedema crisis":1,
"Nivolumab":1,
"caveolin-1":1,
"oncogene":1,
"tumor suppressor gene":1,
"Colocalization":1,
"Colorectal":1,
"Neuroendocrine carcinoma":1,
"Tubular adenoma":1,
"Benign mixed parotid tumor":1,
"Facial spasm":1,
"Pleomorphic adenoma":1,
"Reconstructive surgery":1,
"Salivary glands":1,
"Adrenal oncocytoma":1,
"Robotic adenalectomy":1,
"Bleeding macroadenoma":1,
"Oncocytoma adenohypophysis":1,
"Pituitary bleeding":1,
"Pituitary gland":1,
"Rare pituitary neoplasm":1,
"Spindle cell oncocytoma":1,
"Adenoid cystic carcinoma":1,
"Micro papillary thyroid carcinoma":1,
"Stridor":1,
"Trachea":1,
"fine-needle aspirate":1,
"fine-needle aspiration supernatant":1,
"Poly r(C) binding protein":1,
"miR-490-3p":1,
"High resolution melting (HRM) analysis":1,
"Meta-analysis":1,
"Prophylactic central neck dissection":1,
"cN0":1,
"Drug resistance":1,
"LY3009120":1,
"Obatoclax":1,
"Vemurafenib":2,
"Endometrial neoplasms":1,
"Post-menopausal bleeding":1,
"Leiomyosarcoma thyroid":1,
"Malignant fibrous histiocytoma thyroid":1,
"Sarcoma thyroid":1,
"Thyroid mass lesion":1,
"Benign":1,
"Calcification":1,
"Thyroid parenchyma":1,
"Advanced thyroid cancer":1,
"Lenvatinib":1,
"Tracheal infiltration":1,
"Tyrosine kinase inhibitor":1,
"BRAF V600E mutation":1,
"Biología molecular":1,
"Carcinoma papilar de tiroides":1,
"Inmunohistoquímica":1,
"Mutación BRAF V600E":1,
"PCR en tiempo real":1,
"Real time PCR":1,
"Bone metastases":1,
"temporal":1,
"GH deficiency":1,
"rhGH replacement":1,
"risk factors":1,
"cordectomy":1,
"glottis insufficiency":1,
"thyroplasty":1,
"unilateral vocal fold paralysis":1,
"voice quality":1,
"Clinical outcomes":1,
"Multifocal macroscopic papillary thyroid cancer":1,
"Thyroid cancer recurrence":1,
"intraoperative PTH":1,
"intrathryoidal parathyroid":1,
"parathyroid cancer":1,
"tertiary hyperparathyroidism":1,
"dabrafenib":1,
"radioactive iodine":1,
"AASLD, American Association for the Study of Liver Diseases":1,
"ADV, adefovir dipivoxil":1,
"ALT, alanine aminotransferase":1,
"APASL, Asian Pacific Association for the Study of the Liver":1,
"ART, antiretroviral therapy":1,
"AST, aspartate aminotransferase":1,
"Anti-HBe, antibodies to hepatitis B envelope antigen":1,
"CBC, complete blood count":1,
"CDC, Center for Disease Control":1,
"CHB, chronic hepatitis B":1,
"CU-HCC, Chinese University-Hepatocellular Carcinoma":1,
"DAA, direct-acting antiviral":1,
"DILI, drug induced liver injury":1,
"DNA, deoxyribonucleic acid":1,
"EASL, European Association for the Study of the Liver":1,
"ETV, entecavir":1,
"GAG-HCC, Guide with Age, Gender, HBV DNA, Core Promoter Mutations and Cirrhosis-Hepatocellular Carcinoma":1,
"GGT, gamma-glutamyl transferase":1,
"GRADE, Grading of Recommendations Assessment Development and Evaluation":1,
"HBIG, hepatitis B immune globulin":1,
"HBV, hepatitis B virus":1,
"HBeAg, hepatitis B envelope antigen":1,
"HCC, hepatocellular carcinoma":1,
"HCV, hepatitis C virus":1,
"HDV, hepatitis D virus":1,
"HIV, human immunodeficiency virus":1,
"IFN-α, interferon alpha":1,
"INASL, Indian National Association for Study of the Liver":1,
"INR, international normalized ratio":1,
"KASL, Korean Association for the Study of the Liver":1,
"LAM, lamivudine":1,
"NA, nucleos(t)ide analogue":1,
"PAGE-B, platelets, age, gender—hepatitis B":1,
"PVNR, primary virological non-response":1,
"PVR, partial virological response":1,
"PegIFN-α, pegylated interferon alpha":1,
"RCT, randomized controlled trial":1,
"REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B":1,
"SOVR, sustained off-therapy virological response":1,
"TAF, tenofovir alafenamide":1,
"TDF, tenofovir disoproxil fumarate":1,
"TDV, telbivudine":1,
"TSH, thyroid-stimulating hormone":1,
"VR, virologic response":1,
"WHO, World Health Organization":1,
"anti-HBs, antibody to hepatitis B surface antigen":1,
"cccDNA, covalently closed circular DNA":1,
"chronic hepatitis":1,
"cirrhosis":1,
"eGFR, estimated glomerular filtration rate":1,
"hepatitis B":1,
"jaundice":1,
"liver failure":1,
"MicroPure system with ultrasonography":1,
"monochrome super micro vascular imaging":1,
"Hashimoto's encephalopathy":1,
"¹³¹I radiotherapy":1,
"Cancer progression":1,
"HPV":1,
"Oncology":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2017年2月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
